Business Wire

ProTek Fiber expands full-fiber connectivity in rural Illinois with Adtran

Share

News summary: Service provider required flexible technology to deliver fast, reliable broadband to 10,000 homes in underserved and unserved areas Adtran’s disaggregated fiber access platform scales rapidly, enabling ProTek Fiber to bring full-fiber internet to communities in five counties Deployment includes Adtran’s ALM with deep PON assurance for fast, efficient fiber fault localization and resolution across the FTTX network

Adtran today announced that ProTek Fiber is harnessing its flexible fiber access technology, including its Mosaic One SaaS and ALM fiber monitoring solution with deep PON assurance, to deliver full-fiber internet to underserved areas in Illinois. The deployment marks ProTek Fiber’s transition to fiber optic technology, having previously operated as a leading wireless internet service provider (WISP). Using Adtran’s AI-driven disaggregated solution, ProTek Fiber has begun offering high-quality broadband to residential subscribers. The expansion of the network enables thousands of people to work and study from home and access services such as telemedicine. The deployment is also expected to boost economic activity across the region.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250108386418/en/

Adtran’s fiber access technology is helping ProTek Fiber deliver high-speed broadband to long-underserved regions. (Photo: Business Wire)

“Adtran’s Mosaic One and scalable fiber access hardware enables us to rapidly and cost-effectively expand our network to bring fast, high-quality broadband into long-underserved areas. Together, we’re closing the digital divide across a diverse range of rural communities in Williamson, Jackson, Franklin, Johnson and Union counties,” said Cameron McCurdy, CEO of ProTek Fiber. “We were also able to deploy Adtran’s ALM fiber monitoring platform with unique deep PON assurance technology to monitor the health of our network in real-time. With ALM, we get instant, detailed alerts that provide early warnings about impending fiber issues. This enables us to manage our resources more effectively and ensures subscribers will always receive the best possible online experience.”

Adtran’s SDX 6000 Series Combo PON OLTs facilitate the efficient expansion of ProTek Fiber’s network, while its SDX 630 Series ONTs deliver full-fiber connectivity directly into residences. ProTek Fiber is also leveraging Adtran’s SDGs, including SDG 8700 Series Wi-Fi 7 devices, to ensure reliable wireless coverage throughout the home. Through Adtran’s Mosaic One, ProTek Fiber gains actionable insights from a unified interface, simplifying network management and optimization. Additionally, Mosaic One Marketing Center enables ProTek Fiber to develop targeted marketing campaigns that increase revenue. The deployment also features Adtran’s ALM platform with deep PON assurance, enabling real-time, in-service fault detection and precise localization within the PON infrastructure – even behind splitters and without the need for demarcation reflectors. This boosts service quality, minimizes truck rolls and maximizes uptime across rural areas.

“With our Mosaic One platform, modular fiber access hardware, and ALM with deep PON assurance, ProTek Fiber can rapidly expand its network, bringing thousands of people in rural Southern Illinois into the Gigabit age. Our technology also empowers ProTek Fiber to seamlessly and cost-effectively scale capacity to meet rising data demand,” commented Jeremy Harris, VP of North America service provider sales at Adtran. “With the deployment of this intelligence-driven full-fiber network, many people have quickly gone from having poor or even no broadband access to receiving world-class connectivity. Expanding the availability of full-fiber internet in rural regions always has a transformative impact on communities. We’re proud to have played our part in this important project and look forward to further collaborations with ProTek Fiber.”

About Adtran

ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.

About ProTek

Protek Fiber was founded to provide broadband to Unserved and Underserved customers in Southern Illinois. In 2023 Protek Internet became ProTek Fiber. The original management team has grown Protek Fiber to be one of the leading, locally owned, and operated internet/IT service providers in Illinois. Protek Fiber’s rapidly expanding footprint is providing Broadband, paired with excellent customer service to Marion/Carbondale, and surrounding rural Southern Illinois area. www.protekweb.com

Published by 
ADTRAN Holdings, Inc. 
www.adtran.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20250108386418/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ImmunAbs Announces FDA Phase 2 IND Approval of IM-101, a Novel Complement C5 Inhibitor, for Treatment of Myasthenia Gravis2.6.2025 13:00:00 CEST | Press release

ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial evaluating the safety and efficacy of IM-101, a novel complement C5 inhibitor, for the treatment of Myasthenia Gravis. The forthcoming multicenter, randomized, double-blind, placebo-controlled study will enroll up to 90 patients to evaluate the effectiveness and safety of monthly IM-101 dosing in relieving complement-induced symptoms in MG. “This IND approval is pivotal for us as it brings us one step closer to delivering a transformative therapy for patients with autoimmune disorders”, said Dr. Dongjo Kim, the CEO of ImmunAbs, “we believe IM-101 has the potential to deliver deeper therapeutic responses and more durable remissions in patients who have failed to achieve sustained remission with current approved treatment.” About Myasthenia Gravis

Lenovo and Bellevue University Team Up to Offer Supply Chain and Logistics Education to Deliver “Smarter Technology for All”2.6.2025 13:00:00 CEST | Press release

Learners will have access to Lenovo’s globally recognized supply chain expertise through real-world case studies and subject matter experts. Lenovo, the global technology powerhouse, recognized in the top 10 in the Gartner Supply Chain Top 25, and Bellevue University, one of the nation’s top online universities, are teaming up to develop the next generation of supply chain professionals. “We believe that bringing real-world Global Supply Chain experience and learning directly into an education curriculum is precisely the optimal way to upskill the workforce of the future,” said Ben Massie, Vice President, Global Supply Chain, Lenovo. “Teaming up with Bellevue allows us to attract the right talent using the right technology and deliver on our mission to make ‘smarter technology for all’ a reality.” As a preferred higher education institution tapped to team up with Lenovo to offer supply chain short-term learning, Bellevue will leverage the breadth and depth of Lenovo’s supply chain expe

Lifezone Metals Files Initial Assessment for the Kabanga Nickel Project in Tanzania2.6.2025 12:30:00 CEST | Press release

Vertically Integrated Plan includes Hydrometallurgical Refinery at Kahama $2.37 Billion After-Tax NPV (8%) and 22.9% After-Tax IRR at $8.49 per Pound Nickel Price Initial Assessment Proposes a 22-Year Mine Plan at Average 2.39% Nickel Equivalent Grade Webcast with Technical Leadership Team at 10 AM ET on Tuesday, June 3, 2025 Lifezone Metals Limited’s (NYSE: LZM) Chief Executive Officer, Chris Showalter, and Chief Operating Officer, Gerick Mouton, announce today the results from the Initial Assessment for its flagship Kabanga Nickel Project in northwest Tanzania. The Initial Assessment evaluates a vertically integrated mining, processing and refining operation, commencing with a high-grade nickel sulfide underground mine and concentrator at the Kabanga site, followed five years later by a hydrometallurgical refinery at Kahama. The study covers the Main, MNB, Kima, North, and Tembo zones and is based on the December 2024 Mineral Resource Update (refer to Lifezone’s December 5, 2024 news

Corpay Cross-Border Named an Official Partner of Real Madrid C.F.2.6.2025 12:00:00 CEST | Press release

Providing access to currency risk management and cross-border payments solutions Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into an agreement with Real Madrid C.F. to become an Official Partner. Through this partnership, Real Madrid will be able to gain access to and utilise Corpay Cross Border’s innovative solutions to help mitigate foreign exchange exposure from their day-to-day business needs. "The Corpay Cross-Border team is elated to be named an Official Partner of Real Madrid, one of the world’s most widely recognized and followed sports franchises," said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. “With our strong focus on growing the Corpay brand, as well as our currency risk management business, we are excited to partner with one of the most successful football clubs in the world.” About Corpay Corpay, Inc. (NYSE: CPAY) is a global S&P500 corporate payments co

BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 20252.6.2025 12:00:00 CEST | Press release

Preliminary results highlight anti-tumor activity and favorable safety profiles of both B7-H4-targeting ADC and CDK2 inhibitorData underscore strength of emerging breast cancer pipeline as part of BeOne’s global transformation with next wave of innovation BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, announced new clinical data from its emerging breast cancer pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Poster presentations feature preliminary results of the dose escalation studies of two investigational molecules: BG-C9074, a novel B7-H4-targeting antibody-drug conjugate (ADC) in patients with advanced solid tumors, including breast cancer, and BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), in HR+/HER2- breast cancer patients with prior CDK4/6i exposure. “Presenting the first clinical data for two novel breast cancer candidates at ASCO 2025 marks a pivotal moment for BeOne,” said Mark Lanas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye